Silo Pharma, Inc.
SILO
$2.15
-$0.13-5.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 0.00% | |||
| Cost of Revenue | -- | 0.00% | |||
| Gross Profit | -- | 0.00% | |||
| SG&A Expenses | 8.95% | 21.09% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -42.40% | 100.43% | |||
| Operating Income | 41.75% | -102.76% | |||
| Income Before Tax | 49.44% | -86.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 49.44% | -86.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 49.44% | -86.85% | |||
| EBIT | 41.75% | -102.76% | |||
| EBITDA | 41.82% | -103.13% | |||
| EPS Basic | 57.93% | -82.35% | |||
| Normalized Basic EPS | 52.95% | -82.81% | |||
| EPS Diluted | 57.93% | -82.35% | |||
| Normalized Diluted EPS | 52.95% | -82.81% | |||
| Average Basic Shares Outstanding | 20.20% | 2.47% | |||
| Average Diluted Shares Outstanding | 20.20% | 2.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||